Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AXIN1
REST API REST API
Homo sapiens
AXIN1 is differentially expressed in 172 experiments: 74 organism parts: bone marrow, liver, ... (72 more);, 104 disease states: normal, control, ... (102 more);, 55 cell types 166 cell lines 25 compound treatments and 60 other conditions.
Orthologs AXIN1 (Bos taurus)   AXIN1 (Gallus gallus)   Q4H3V5_CIOIN (Ciona intestinalis)   Axin1 (Mus musculus)   Axin1 (Rattus norvegicus)   axin1 (Danio rerio)   Axn (Drosophila melanogaster)   axin1 (Xenopus laevis)   AXIN1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, protein binding, apoptosis, positive regulation of peptidyl-threonine phosphorylation, cytoplasm, protein catabolic process, beta-catenin binding, positive regulation of proteasomal ubiquitin-dependent protein catabolic process, cytoplasmic microtubule organization, intracellular, cell cortex, protein complex, protein homooligomerization, positive regulation of protein ubiquitination, protein domain specific binding, neurological system process, positive regulation of transforming growth factor beta receptor signaling pathway, negative regulation of Wnt receptor signaling pathway, adult walking behavior, signal transducer activity, positive regulation of JNK cascade, soluble fraction, positive regulation of protein kinase activity, identical protein binding, GTPase activator activity, activation of JUN kinase activity, Wnt receptor signaling pathway, multicellular organismal development, sensory perception of sound, protein kinase binding, protein self-association, nucleus, protein polyubiquitination, postsynaptic density, cytoplasmic microtubule, canonical Wnt receptor signaling pathway, cell death, cytoplasmic membrane-bounded vesicle, cytoplasmic vesicle, perinuclear region of cytoplasm, protein homodimerization activity, SMAD binding, protein C-terminus binding, activation of protein kinase activity, nucleocytoplasmic transport, determination of left/right symmetry, enzyme binding, signal transduction, lateral plasma membrane, positive regulation of transcription, DNA-dependent, positive regulation of GTPase activity, dorsal/ventral axis specification, ubiquitin protein ligase binding, beta-catenin destruction complex, positive regulation of peptidyl-serine phosphorylation, armadillo repeat domain binding, negative regulation of protein metabolic process, cellular protein complex assembly, olfactory placode formation, in utero embryonic development, positive regulation of protein catabolic process, axial mesoderm development, protein complex scaffold, embryonic eye morphogenesis, axial mesoderm formation, erythrocyte homeostasis, plasma membrane part, embryonic skeletal joint morphogenesis, tail morphogenesis, negative regulation of fat cell differentiation, genetic imprinting, p53 binding, positive regulation of ubiquitin-protein ligase activity, negative regulation of canonical Wnt receptor signaling pathway, Axin-APC-beta-catenin-GSK3B complex, R-SMAD binding, hemoglobin metabolic process, I-SMAD binding, Wnt receptor signaling pathway involved in somitogenesis, muscle cell development, regulation of protein phosphorylation, canonical Wnt receptor signaling pathway involved in neural plate anterior/posterior pattern formation, optic placode formation, Wnt receptor signaling pathway involved in forebrain neuron fate commitment, positive regulation of protein phosphorylation, negative regulation of transcription elongation from RNA polymerase II promoter, cell periphery, regulation of catenin import into nucleus, APC-Axin-1-beta-catenin complex, cellular response to organic cyclic compound, positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process, forebrain anterior/posterior pattern specification, termination of G-protein coupled receptor signaling pathway
InterPro Term Regulat_G_prot_signal, DIX, Axin_b-cat-bd
UniProt Accession O15169, B1AH42
Gene-Disease Assocation CAUDAL DUPLICATION ANOMALY, HEPATOCELLULAR CARCINOMA
Search EB-eye ENSG00000103126
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-MEXP-1251, E-MTAB-24, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-18005, E-GEOD-24147, ... (24 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-3529, E-GEOD-20081
PC3
2
E-GEOD-5258, E-MEXP-2034
U251
2
E-GEOD-20089, E-MTAB-62
MT3
1
E-MTAB-37
KHOS240S
1
E-MTAB-37
NA19102
1
E-GEOD-19480
160 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-4219, E-GEOD-13987, ... (30 experiments)

Factor Value U/D Experiments
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
fibroblast
1
2
E-GEOD-26672, E-GEOD-3920, E-GEOD-3204
spheroid recovery
1
E-GEOD-4219
testis - leydig cell
1
E-AFMX-5
adipose stem cells derived from adult human donor
1
E-GEOD-20033
endothelial cells and pericytes
1
E-MEXP-1251
49 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-25, E-GEOD-15960, E-GEOD-2466, E-GEOD-20602, ... (34 experiments)

Factor Value U/D Experiments
gastric carcinoma
2
E-GEOD-2685, E-MTAB-37
glioblastoma
2
E-MTAB-37, E-GEOD-4290
hepatocellular carcinoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-37, E-MTAB-62
breast cancer, adenovirus expressing GFP
1
E-MTAB-62
Crohn's disease
1
E-GEOD-3365
98 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-15205, E-GEOD-5824, E-TABM-868, ... (20 experiments)

Factor Value U/D Experiments
none
2
6
E-GEOD-2803, E-TABM-868, E-MEXP-1958, E-GEOD-20719, E-MEXP-1601, ... (8 experiments)
control
2
E-GEOD-995, E-GEOD-3284
bacterial endotoxin
1
E-GEOD-3284
valproic acid
1
E-GEOD-1615
Cxcl12
1
E-GEOD-7307
mercaptopurine, methotrexate
1
E-GEOD-412
19 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-21138

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-6431, E-MEXP-2340

Genotype
studied in E-GEOD-2466, E-GEOD-21750, E-GEOD-18005, E-GEOD-1153

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-MEXP-2657, E-MEXP-1446, E-GEOD-10315, E-MEXP-1103, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-TABM-666, E-GEOD-19519, ... (22 experiments)

Infection
studied in E-GEOD-12254

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540

Phenotype
studied in E-GEOD-21750, E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-2466

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Vehicle
studied in E-GEOD-5258

Processing time: 0.295 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM